Computational Approaches in Theranostics: Mining and Predicting Cancer Data
Open accessThe DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.
Abstract
The ability to understand the complexity of cancer-related data has been prompted by the applications of (1) computer and data sciences, including data mining, predictive analytics, machine learning, and artificial intelligence, and (2) advances in imaging technology and probe development. Computational modelling and simulation are systematic and cost-effective tools able to identify important temporal/spatial patterns (and relationships), characterize distinct molecular features of cancer states, and address other relevant aspects, including tumor detection and heterogeneity, progression and metastasis, and drug resistance. These approaches have provided invaluable insights for improving the experimental design of therapeutic delivery systems and for increasing the translational value of the results obtained from early and preclinical studies. The big question is: Could cancer theranostics be determined and controlled in silico? This review describes the recent progress in the development of computational models and methods used to facilitate research on the molecular basis of cancer and on the respective diagnosis and optimized treatment, with particular emphasis on the design and optimization of theranostic systems. The current role of computational approaches is providing innovative, incremental, and complementary data-driven solutions for the prediction, simplification, and characterization of cancer and intrinsic mechanisms, and to promote new data-intensive, accurate diagnostics and therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic illustration of the refinement process involving several integrative approaches and powered by new income and technologies. Adapted from [48]. Copyright Taylor & Francis, 2016.](https://figures.cochat.ai/paper-figures/80c45b257c89465da319bcb80f55c667/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-1.jpg)
![Figure 2 Schematic representation of the iterative optimization workflow, reflecting the data integration/analysis and the development/optimization processes of the computational model. Reprinted from [65] under a CC BY 4.0 License. Copyright Ogilvie, L.A., Kovachev, A., Wierling, C., Lange, B.M.H. and Lehrach, H., 2017.](https://figures.cochat.ai/paper-figures/f407f45ce136413da7b7a51dd2bbc8ed/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-2.jpg)
![Figure 3 Representative 3D snapshots of the tumor response over time (t = 40, 80, 120, 200 h) and considering three drug-treatment scenarios: doxorubicin alone (Dox), sunitinib alone, and treatment with combined drugs (Dox + sunitinib). Reprinted from [111] under a CC BY 2.0 License. Copyright Wang, J., Zhang, L., Jing, C., Ye, G., Wu, H., Miao, H., Wu, Y. and Zhou, X., 2013.](https://figures.cochat.ai/paper-figures/7a19786bd4754364b2ffcbd59b2ef680/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-3.jpg)
![Figure 4 A schematic representation of the two-dimensional projection of cellular landscape of tumor microenvironment. (a) Data from The Cancer Genome Atlas (TCGA) were analyzed and represented in a two-dimensional tumor microenvironment landscape map resorting to t-distributed stochastic neighborhood embedding (t-SNE) based on the scores reflecting the enrichment of cell types. (b) Gradient color representing the tumor metabolism index (TMI) of each sample, showing that hypometabolic samples are placed within populations with low values. (c) Circular dendrogram for the groups identified by hierarchical cluster analysis. (d) Two-dimensional map of the tumor microenvironment landscape reflecting the similarity between samples. (e) Selected clusters displaying significantly different tumor metabolic index (TMI). (f) Two-dimensional map of the tumor microenvironment landscape with the ImmuneScore information. (g) ImmuneScores were significantly different between the clusters. (h) A composed view of the results including the heatmap showing the scores of the enrichment of each immune cell type, the tumor metabolism index, the groups identified based on immune cellular heterogeneity, lung adenocarcinoma subtypes, and ImmuneScore. Reprinted from [113] under a CC BY-NC 4.0 license. Copyright Ivyspring International Publisher, 2018.](https://figures.cochat.ai/paper-figures/02dccc98be24443aaa89c06c65dcef2c/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-4.jpg)
![Figure 5 (a) Scheme of the modelling workflow, (b) Simulation dynamics results of the tumor growth in a virtual mouse after treatment with OT-1 T-cells and anti-CD137 monoclonal antibody, obtained at days 7, 41, 16, 20, 24, and 28 (from upper-left to lower-right). The effect of anti-CD137 in tumor infiltration is confirmed by the increased TC cell cytotoxicity and by the chemotaxis gradients. (c,d) Model prediction results obtained from the in silico study suggesting that the combined therapy with OT-1 T-cells and anti-CD137 monoclonal antibody) was not efficient in eliminating murine B16OVA melanoma with no expression of CD137 on endothelium (c). When comparing with wild-type in silico mice, the CD8 T cell infiltration was drastically reduced and delayed in time (d). Adapted from [116] under a CC BY 4.0 License. Copyright Pappalardo, F., Forero, I.M., Pennisi, M., Palazon, A., Melero, I. and Motta S., 2011.](https://figures.cochat.ai/paper-figures/28ef2d1cec7e47508a9e438a02f3781e/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-5.jpg)
![Figure 6 Membrane interaction and internalization of the polyarabic-coated magnetite nanoparticle, MAG-ARA. (a) Initial configuration of MAR-ARA in vacuum. (b) Final configuration of MAR-ARA in contact with a dipalmitoyl phosphatidylcholine (DPPC) bilayer. (c) Example of the interactions of l-arabinose and d-galactose with DPPC. (d) Confocal fluorescence image and a bright filed image from human breast cancer cells incubated with MAG-ARA, left, and control nanoparticles, right. Reprinted from [44] under a CC BY 4.0 license. Copyright Patitsa, M., Karathanou, K., Kanaki, Z., Tzioga, L., Pippa, N., Demetzos, C., Verganelakis, D.A., Cournia, Z. and Klinakis, A., 2017.](https://figures.cochat.ai/paper-figures/2e1f5a99c7a04960852ddd7afe414ab1/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-6.jpg)
![Figure 7 (A) UV−vis absorption spectra of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at different (AEMA):(HAuCl4) molar ratios. (B) Transmission Electron Microscopy (TEM) image and (C) XRD plot of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at (AEMA):(HAuCl4) molar ratio of 5. (D) Density profiles of different beads and (E) cross-section views of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at different (AEMA):(HAuCl4) molar ratios. Reprinted with permission from [139]. Copyright American Chemical Society, 2017.](https://figures.cochat.ai/paper-figures/ff974ebd9e7841daa6d5aefd3129a4c6/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-7.jpg)
![Figure 8 (A) Loading content, entrapment efficiency and sizes of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX as a function of mDOX/mmicelle. (B) Density profiles of different beads and (C) cross-section views of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX micelles at different weight ratios. (D) In vitro drug release profiles of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX at different pH levels. Reprinted with permission from [139]. Copyright American Chemical Society, 2017.](https://figures.cochat.ai/paper-figures/db6b1f4f5e4e4d54af0a6b4731011c46/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-8.jpg)
![Figure 9 (a,b) Illustrative description of the strategy used for detecting liver metastatic colorectal tumors using halofluorochromic polymer nanoassemblies (PNAs) and computational simulations. (c,d) Simulation results reflecting the distribution of the nanoparticles in metastatic tumors at (c) 1.8 h and (d) 12 h, after systemic injection of the nanoparticles for three different degrees of vascularization. Red refers to viable tumor tissue, blue reflects enclosing hypoxic tissue, and brown reflects necrotic regions. The rectangular grid represents the capillary network, displaying irregular sprouts, which simulate the angiogenesis effect and the growth of blood vessel. Reprinted with permission from [147]. Copyright Springer Nature, 2017.](https://figures.cochat.ai/paper-figures/ad71db2203bb41acb5f4be52bd6eac07/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-9.jpg)
![Figure 10 (a–c) General procedure of the spectral Fiedler field (SFF) method which includes (a) a raw image in gray scale, (b) the matrix representation of (a), and (c) the resulting contrast matrix. Using the matrix from of each gray scale image, the method is applied to a small region centered at every single pixel, generating the contrast matrix, which is then processed using a low pass filter for removing noise. The final matrix represents the SFF map. (d) Hematoxylin and eosin image of colon tumor. (e) Pattern obtained using CD31 endothelial cell marker. (f) Fluorescence of the drug in tumors. (g) SFF map of echogenic liposomes enhanced ultrasound contrast in tumor areas displaying a positive response for CD31 endothelial cell marker. (h) Relative drug diffusion considering the positive regions in SFF map. (i) Normalized distribution of doxorubicin combined with doxorubicin fluorescence image. Purple shades refer to doxorubicin fluorescence while blue-red corresponds to the spectral shades of doxorubicin distribution. Reprinted from [175] under a CC BY 4.0 License. Copyright Liu, C., Kapoor, A., VanOsdol, J., Ektate, K., Kong, Z., and Ranjan, A., 2018.](https://figures.cochat.ai/paper-figures/6d482c03b5884a3283c945dd58d74c5f/computational-approaches-in-theranostics-mining-and-predicting-cancer-data-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, on the other side of the argument, interactions in reactive non-neoplastic cells, genetically-altered tumor cells, and ECM control the majority of the stages of tumorigenesis effectively including clonal evolution, cancer heterogeneity, epithelial-mesenchymal-transition (EMT), migration, invasion, development of metastasis, neovascularization, apoptosis and chemotherapeutic drug resist”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132 · cited 2×
“The correlation between a prognostic radiomic signature, capturing intratumor heterogeneity and gene expression patterns, was established based on a radiogenomics analysis [169].”
MethodSystems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Multi-omics approaches to disease
Hasin, Y., Seldin, M., & Lusis, A. (2017) · Genome Biology · doi:10.1186/s13059-017-1215-1 · Cited by 2,953
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,234
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
Applications of Support Vector Machine (SVM) Learning in Cancer Genomics
(2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20063 · Cited by 1,528
Deep learning for computational biology
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156651 · Cited by 1,473
Graham, M. V., Purdy, J. A., Emami, B., Harms, W., Bosch, W., Lockett, M. A., & Perez, C. A. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00183-2 · Cited by 1,223
Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis
Kuznetsov, V. A., Makalkin, I. A., Taylor, M. A., & Perelson, A. S. (1994) · Bulletin of Mathematical Biology · doi:10.1007/bf02460644 · Cited by 1,061
Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., Kinoshita, T., Saito, N., Ochiai, A., Tomita, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4806 · Cited by 956
Modeling immunotherapy of the tumor - immune interaction
Kirschner, D., & Panetta, J. C. (1998) · Journal of Mathematical Biology · doi:10.1007/s002850050127 · Cited by 915
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
Using Machine Learning Algorithms for Breast Cancer Risk Prediction and Diagnosis
Asri, H., Mousannif, H., Moatassime, H. A., & Noel, T. (2016) · Procedia Computer Science · doi:10.1016/j.procs.2016.04.224 · Cited by 772
Yan, D., Vicini, F., Wong, J., & Martinez, A. (1997) · Physics in Medicine and Biology · doi:10.1088/0031-9155/42/1/008 · Cited by 761
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
de Pillis, L. G., Gu, W., & Radunskaya, A. E. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.06.037 · Cited by 575
Chemometrics in metabolomics—A review in human disease diagnosis
Madsen, R., Lundstedt, T., & Trygg, J. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.11.042 · Cited by 557
Molecular Imaging with Theranostic Nanoparticles
Jokerst, J. V., & Gambhir, S. S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200106e · Cited by 548
De novo design of potent and selective mimics of IL-2 and IL-15
Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature · doi:10.1038/s41586-018-0830-7 · Cited by 531 · cited 1×
“Very recently, Baker and co-workers [135] have used computer modeling for designing proteins that reproduce the binding sites of cytokines.”
MethodGenetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Deisboeck, T. S., Wang, Z., Macklin, P., & Cristini, V. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124729 · Cited by 458
‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics
Horgan, R. P., & Kenny, L. C. (2011) · The Obstetrician & Gynaecologist · doi:10.1576/toag.13.3.189.27672 · Cited by 456
A comprehensive urinary metabolomic approach for identifying kidney cancer
Kind, T., Tolstikov, V., Fiehn, O., & Weiss, R. H. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.028 · Cited by 449
Chan, E. C. Y., Koh, P. K., Mal, M., Cheah, P. Y., Eu, K. W., Backshall, A., Cavill, R., Nicholson, J. K., & Keun, H. C. (2009) · Journal of Proteome Research · doi:10.1021/pr8006232 · Cited by 444
Advances in Image-Guided Radiation Therapy
Dawson, L. A., & Jaffray, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9515 · Cited by 420
Fehr, D., Veeraraghavan, H., Wibmer, A., Gondo, T., Matsumoto, K., Vargas, H. A., Sala, E., Hricak, H., & Deasy, J. O. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505935112 · Cited by 382
Schütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Onco-Multi-OMICS Approach: A New Frontier in Cancer Research
Chakraborty, S., Hosen, M. I., Ahmed, M., & Shekhar, H. U. (2018) · BioMed Research International · doi:10.1155/2018/9836256 · Cited by 335
Klipp, E., Liebermeister, W., Wierling, C., Kowald, A., Lehrach, H. R., & Herwig, R. (2009) · Cited by 308
Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery
Kim, K., Aronov, P., Zakharkin, S. O., Anderson, D., Perroud, B., Thompson, I. M., & Weiss, R. H. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800165-mcp200 · Cited by 271
The statistical mechanics of complex signaling networks: Nerve growth factor signaling.
Brown, K. S., Hill, C. C., Calero, G. A., Myers, C. R., Lee, K. H., Sethna, J. P., & Cerione, R. A. (2004) · Physical Biology · doi:10.1088/1478-3967/1/3/006 · Cited by 265 · cited 1×
“These results had direct implications in the perception of the effects BRAF alteration on the RAF/ERK and PI3K/AKT pathways [103].”
BackgroundMetabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications
Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., & Di Leo, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7550 · Cited by 246
Early Stage Diagnosis of Oral Cancer Using 1H NMR–Based Metabolomics
Tiziani, S., Lopes, V., & Günther, U. L. (2009) · Neoplasia · doi:10.1593/neo.81396 · Cited by 237
On the Integration of In Silico Drug Design Methods for Drug Repurposing
March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00298 · Cited by 235 · cited 2×
“r r r i [ ] l fit fr t ti l i i t , ll i t r ti li re ict important drug–target an drug–cancer relationships by integrati g network‐, ligand‐ and structure‐based approaches, machine learni g, and molecular docking [64].”
BackgroundMolecular targeted therapy of cancer: The progress and future prospect
Ke, X., & Shen, L. (2017) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2017.06.001 · Cited by 231
Wu, M., Frieboes, H. B., McDougall, S. R., Chaplain, M. A. J., Cristini, V., & Lowengrub, J. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.11.031 · Cited by 229
Reverse engineering and identification in systems biology: strategies, perspectives and challenges
Villaverde, A. F., & Banga, J. R. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.0505 · Cited by 229 · cited 1×
“Different statistical methods, including Bayesian estimations and optimization techniques, have been applied to identify unknown model parameters [59,60].”
MethodCancer immunotherapy, mathematical modeling and optimal control
Castiglione, F., & Piccoli, B. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.04.003 · Cited by 211
YANG, J., XU, G., ZHENG, Y., KONG, H., PANG, T., LV, S., & YANG, Q. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.09.032 · Cited by 210
Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer
Vandenberghe, M. E., Scott, M. L. J., Scorer, P. W., Söderberg, M., Balcerzak, D., & Barker, C. (2017) · Scientific Reports · doi:10.1038/srep45938 · Cited by 209
Xie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202
Gao, H., Lu, Q., Liu, X., Cong, H., Zhao, L., Wang, H., & Lin, D. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01086.x · Cited by 194
Molecular imaging for personalized cancer care
Kircher, M. F., Hricak, H., & Larson, S. M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.005 · Cited by 193
Overview of Systems Biology and Omics Technologies
Karahalil, B. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160926150617 · Cited by 187
Metabolite profiling of fecal water extracts from human colorectal cancer
Monleón, D., Morales, J. M., Barrasa, A., López, J. A., Vázquez, C., & Celda, B. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1345 · Cited by 186
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy
Ozdemir-Kaynak, E., Qutub, A. A., & Yeşil-Çeliktaş, Ö. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00170 · Cited by 167
MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer
Bertoli, G. R., Cava, C., & Castiglioni, I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030421 · Cited by 160
Systems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
Issaq, H. J., Nativ, O., Waybright, T., Luke, B., Veenstra, T. D., Issaq, E. J., Kravstov, A., & Mullerad, M. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.01.084 · Cited by 153
Serkova, N. J., Gamito, E. J., Jones, R. H., O’Donnell, C. I., Brown, J. L., Green, S., Sullivan, H. T., Hedlund, T. E., & Crawford, E. D. (2008) · The Prostate · doi:10.1002/pros.20727 · Cited by 148
Kronik, N., Kogan, Y., Vainstein, V., & Agur, Z. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0387-z · Cited by 148
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 147
Kuperstein, I., Bonnet, E., Nguyen, H.-A., Cohen, D., Viara, E., Grieco, L., Fourquet, S., Calzone, L., Russo, C., Kondratova, M., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.19 · Cited by 143
Detection of gene communities in multi-networks reveals cancer drivers
Cantini, L., Medico, E., Fortunato, S., & Caselle, M. (2015) · Scientific Reports · doi:10.1038/srep17386 · Cited by 141
Yin, P. T., Shah, B. P., & Lee, K. (2014) · Small · doi:10.1002/smll.201400963 · Cited by 133
Gao, H., Dong, B., Liu, X., Xuan, H., Huang, Y., & Lin, D. (2008) · Analytica Chimica Acta · doi:10.1016/j.aca.2008.06.051 · Cited by 132
Scalable Parameter Estimation for Genome-Scale Biochemical Reaction Networks
Fröhlich, F., Kaltenbacher, B., Theis, F. J., & Hasenauer, J. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005331 · Cited by 132
Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models
Kronik, N., Kogan, Y., Elishmereni, M., Halevi-Tobias, K., Vuk‐Pavlović, S., & Agur, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015482 · Cited by 131
Sannazzari, G. L., Ragona, R., Redda, M. G. R., Giglioli, F. R., Isolato, G., & Guarneri, A. (2002) · British Journal of Radiology · doi:10.1259/bjr.75.895.750603 · Cited by 127
Metabolomics in breast cancer: A decade in review
McCartney, A., Vignoli, A., Biganzoli, L., Love, R. R., Tenori, L., Luchinat, C., & Leo, A. D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.012 · Cited by 127
Saccenti, E., & Timmerman, M. E. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01029 · Cited by 126
Michael, A., Ball, G., Quatan, N., Wushishi, F., Russell, N., Whelan, J., Chakraborty, P., Leader, D., Whelan, M., & Pandha, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2337 · Cited by 125
PharmGKB: a logical home for knowledge relating genotype to drug response phenotype
Altman, R. B. (2007) · Nature Genetics · doi:10.1038/ng0407-426 · Cited by 124
Quantitative multimodality imaging in cancer research and therapy
Yankeelov, T. E., Abramson, R. G., & Quarles, C. C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.134 · Cited by 123
Vargas, H. A., Veeraraghavan, H., Micco, M., Nougaret, S., Lakhman, Y., Meier, A. A., Sosa, R., Soslow, R. A., Levine, D. A., Weigelt, B., et al. (2017) · European Radiology · doi:10.1007/s00330-017-4779-y · Cited by 121
Champion, C., Quinto, M. A., Morgat, C., Zanotti‐Fregonara, P., & Hindié, E. (2016) · Theranostics · doi:10.7150/thno.15132 · Cited by 113
Modeling and simulation of cancer immunoprevention vaccine
Pappalardo, F., Lollini, P., Castiglione, F., & Motta, S. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti426 · Cited by 108
Omics Profiling in Precision Oncology
Yu, K.-H., & Snyder, M. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o116.059253 · Cited by 107
Integration of metabolomics and transcriptomics in nanotoxicity studies
Shin, T. H., Lee, D. Y., Lee, H., Park, H. J., Jin, M. S., Paik, M., Manavalan, B., Mo, J., & Lee, G. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.1.237 · Cited by 101
A Computational Model for Predicting Nanoparticle Accumulation in Tumor Vasculature
Frieboes, H. B., Wu, M., Lowengrub, J., Decuzzi, P., & Cristini, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056876 · Cited by 100
Cappuccio, A., Elishmereni, M., & Agur, Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0241 · Cited by 100
Monte Carlo Evaluation of Auger Electron–Emitting Theranostic Radionuclides
Falzone, N., Fernández‐Varea, J. M., Flux, G., & Vallis, K. A. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.153502 · Cited by 97
Kaempfer, R. O. R., Gerez, L., Farbstein, H., Madar, L., HIRSCHMANN, O., Nussinovich, R., & Shapiro, A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1778 · Cited by 96
Liu, Y., Gunda, V., Zhu, X., Xu, X., Wu, J., Askhatova, D., Farokhzad, O. C., Parangi, S., & Shi, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605841113 · Cited by 96
Yan, S.-K., Wei, B.-J., Lin, Z.-Y., Yang, Y., Zhou, Z.-T., & Zhang, W.-D. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.06.007 · Cited by 95
Metabolomics In Biomarker Discovery: Future Uses For Cancer Prevention
Kim, Y. S., Maruvada, P., & Milner, J. A. (2008) · Future Oncology · doi:10.2217/14796694.4.1.93 · Cited by 94
A model reduction method for biochemical reaction networks
Rao, S., van der Schaft, A. J., van Eunen, K., Bakker, B. M., & Jayawardhana, B. (2014) · BMC Systems Biology · doi:10.1186/1752-0509-8-52 · Cited by 90
Clinical multi-omics strategies for the effective cancer management
Yoo, B. C., Kim, K., Woo, S. M., & Myung, J. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.08.010 · Cited by 86
Morgan, K. M., Riedlinger, G., Rosenfeld, J., Ganesan, S., & Pine, S. R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00002 · Cited by 82
Artificial intelligence and big data facilitated targeted drug discovery
Liu, B., He, H., Luo, H., Zhang, T., & Jiang, J. (2019) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000290 · Cited by 81
Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Jaeger, S., Igea, A., Arroyo, R., Alcalde, V., Canovas, B., Orozco, M., Nebreda, A. R., & Aloy, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0097 · Cited by 79
Patitsa, M., Karathanou, K., Kanaki, Z., Tzioga, L., Pippa, N., Demetzos, C., Verganelakis, D. A., Cournia, Z., & Klinakis, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00836-y · Cited by 77
Chen, X. S., & Wong, S. T. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00001-3 · Cited by 74
Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia
Dietrich, S., Hüllein, J., Hundemer, M., Lehners, N., Jethwa, A., Capper, D., Acker, T., Garvalov, B. K., Andrulis, M., Blume, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9495 · Cited by 73
Biological network analysis: insights into structure and functions
Ma, X., & Gao, L. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els045 · Cited by 73
Choi, H., & Na, K. J. (2018) · Theranostics · doi:10.7150/thno.23767 · Cited by 73
Computational Nanomedicine: Modeling of Nanoparticle-Mediated Hyperthermal Cancer Therapy
Kaddi, C. D., Phan, J. H., & Wang, M. D. (2013) · Nanomedicine · doi:10.2217/nnm.13.117 · Cited by 70
Rapid response of biallelic BRAF V 600 E mutated hairy cell leukaemia to low dose vemurafenib
Follows, G., Sims, H., Bloxham, D. M., Zenz, T., Hopper, M. A., Liu, H., Bench, A. J., Wright, P., Veer, M. B. V., & Scott, M. A. (2012) · British Journal of Haematology · doi:10.1111/bjh.12201 · Cited by 70
A Machine Learning Approach for the Classification of Kidney Cancer Subtypes Using miRNA Genome Data
Muhamed Ali, A., Zhuang, H., Ibrahim, A., Rehman, O., Huang, M., & Wu, A. (2018) · Applied Sciences · doi:10.3390/app8122422 · Cited by 70
Castelli, D. D., Dastrù, W., Terreno, E., Cittadino, E., Mainini, F., Torres, E., Spadaro, M., & Aime, S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.005 · Cited by 68
Monleón, D., Morales, J. M., Gonzalez-Darder, J. M., Talamantes, F., Cortés, O., Gil‐Benso, R., López-Ginés, C., Cerdá‐Nicolás, M., & Celda, B. (2008) · Journal of Proteome Research · doi:10.1021/pr800110a · Cited by 68
Application of an artificial neural network model for selection of potential lung cancer biomarkers
Ligor, T., Pater, Ł., & Buszewski, B. (2015) · Journal of Breath Research · doi:10.1088/1752-7155/9/2/027106 · Cited by 66
Begum, N. J., Glatting, G., Wester, H., Eiber, M., Beer, A. J., & Kletting, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-56603-8 · Cited by 66
Mal, M., Koh, P. K., Cheah, P. Y., & Chan, E. C. Y. (2009) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3898 · Cited by 64
Reis, Y., Bernardo-Faura, M., Richter, D., Wolf, T. A., Brors, B., Hamacher‐Brady, A., Eils, R., & Brady, N. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028694 · Cited by 64
Modeling the competition between lung metastases and the immune system using agents
Pennisi, M. A., Pappalardo, F., Palladini, A., Nicoletti, G., Nanni, P., Lollini, P., & Motta, S. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s7-s13 · Cited by 64
Lin, W., Zhang, X., Qian, L., Yao, N., Pan, Y., & Zhang, L. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00810 · Cited by 63
SimB16: Modeling Induced Immune System Response against B16-Melanoma
Pappalardo, F., Martínez‐Forero, I., Pennisi, M. A., Palazón, A., Melero, I., & Motta, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026523 · Cited by 62
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Barber, L. J., Davies, M. N., & Gerlinger, M. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.12.001 · Cited by 62
MicroRNA Theranostics in Prostate Cancer Precision Medicine
Matin, F., Jeet, V., Clements, J. A., Yousef, G. M., & Batra, J. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.242800 · Cited by 62
Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination
Sun, X., Bao, J., You, Z., Chen, X., & Cui, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11745 · Cited by 60
NMR-based metabolomics approach to target biomarkers for human prostate cancer
Jordan, K. W., & Cheng, L. L. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.3.389 · Cited by 59
Kogan, Y., Halevi-Tobias, K., Elishmereni, M., Vuk‐Pavlović, S., & Agur, Z. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4166 · Cited by 59
Peyrade, F., Re, D., Ginet, C., Gastaud, L., Allégra, M., Ballotti, R., Thyss, A., Zenz, T., Auberger, P., & Robert, G. (2013) · Haematologica · doi:10.3324/haematol.2012.082404 · Cited by 58
Monte Carlo Simulations and Atomic Calculations for Auger Processes in Biomedical Nanotheranostics
Montenegro, M., Nahar, S. N., Pradhan, A. K., Huang, K. C., & Yu, Y. (2009) · The Journal of Physical Chemistry A · doi:10.1021/jp905323y · Cited by 58
Computational Modeling and Real-Time Control of Patient-Specific Laser Treatment of Cancer
Fuentes, D., Oden, J. T., Diller, K. R., Hazle, J. D., Elliott, A. M., Shetty, A., & Stafford, R. J. (2009) · Annals of Biomedical Engineering · doi:10.1007/s10439-008-9631-8 · Cited by 58
TCSBN: a database of tissue and cancer specific biological networks
Lee, S., Zhang, C., Arif, M., Liu, Z., Benfeitas, R., Bidkhori, G., Deshmukh, S., Shobky, M. A., Lovrić, A., Borén, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx994 · Cited by 58
Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles
Curtis, L. T., Wu, M., Lowengrub, J. S., Decuzzi, P., & Frieboes, H. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144888 · Cited by 56
Röhr, C., Kerick, M., Fischer, A., Kühn, A., Kashofer, K., Timmermann, B., Daskalaki, A., Meinel, T., Drichel, D., Börno, S. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067461 · Cited by 55
Tan, C., Chen, H., & Xia, C. (2009) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.12.010 · Cited by 50
Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.001 · Cited by 50
Bunimovich‐Mendrazitsky, S., Gluckman, J. C., & Chaskalovic, J. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.02.008 · Cited by 49
Multi-scale agent-based modeling on melanoma and its related angiogenesis analysis
Wang, J., Zhang, L., Jing, C., Ye, G., Wu, H., Miao, H., Wu, Y., & Zhou, X. (2013) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-10-41 · Cited by 45
Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack
Henderson, D. A., Ogilvie, L. A., Hoyle, N. R., Keilholz, U., Lange, B. M. H., & Lehrach, H. (2014) · Biotechnology Journal · doi:10.1002/biot.201400109 · Cited by 45
Xi, J., Kim, J., Si, X. A., CORLEY, R. A., Kabilan, S., & Wang, S. (2015) · Theranostics · doi:10.7150/thno.11107 · Cited by 45
How Advances in Imaging Will Affect Precision Radiation Oncology
Jaffray, D. A., Das, S. K., Jacobs, P. M., Jeraj, R., & Lambin, P. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.047 · Cited by 45
Izadyyazdanabadi, M., Belykh, E., Mooney, M. A., Eschbacher, J. M., Nakaji, P., Yang, Y., & Preul, M. C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00240 · Cited by 45
Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors
Geng, L., Wang, Z., Yang, X., Li, D., Lian, W., Xiang, Z., Wang, W., Bu, X., Lai, W., Hu, Z., et al. (2015) · Theranostics · doi:10.7150/thno.12398 · Cited by 44
Data-driven reverse engineering of signaling pathways using ensembles of dynamic models
Henriques, D., Villaverde, A. F., Rocha, M., Saez-Rodriguez, J., & Banga, J. R. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005379 · Cited by 44 · cited 2×
“This can be improved using parameter optimization, onte Carlo, reverse engineering, and model reduction strategies [72,73], as well as artificial intelligence techniques (e.”
MethodTumor Molecular Imaging with Nanoparticles
Cheng, Z., Yan, X., Sun, X., Shen, B., & Gambhir, S. S. (2016) · Engineering · doi:10.1016/j.eng.2016.01.027 · Cited by 43
Immunotherapy with Interleukin-2: A Study Based on Mathematical Modeling
Banerjee, S. (2008) · International Journal of Applied Mathematics and Computer Science · doi:10.2478/v10006-008-0035-6 · Cited by 42
Zhang, R., Glaser, A. K., Andreozzi, J. M., Jiang, S., Jarvis, L. A., Gladstone, D. J., & Pogue, B. W. (2016) · Journal of Biophotonics · doi:10.1002/jbio.201500344 · Cited by 40
2016 New Horizons Lecture: Beyond Imaging—Radiology of Tomorrow
Hricak, H. (2018) · Radiology · doi:10.1148/radiol.2017171503 · Cited by 39
Biological Networks for Cancer Candidate Biomarkers Discovery
Yan, W., Xue, W., Chen, J., & Hu, G. (2016) · Cancer Informatics · doi:10.4137/cin.s39458 · Cited by 38
A First Attempt to Bring Computational Biology into Advanced High School Biology Classrooms
Gallagher, S. R., Coon, W., Donley, K., Scott, A., & Goldberg, D. S. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002244 · Cited by 37
Cava, C., Bertoli, G. R., & Castiglioni, I. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1535-2 · Cited by 37
van Miltenburg, M. H., & Jonkers, J. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.01.004 · Cited by 36
Wang, J., Ye, H., Zhang, D., Cheng, K., Hu, Y., Yu, X., Lü, L., Hu, J., Zuo, C., Qian, B., et al. (2017) · Theranostics · doi:10.7150/thno.18262 · Cited by 35
Keilholz, U., Scheibenbogen, C., Stoelben, E., Saeger, H., & HUNSTEIN, W. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90122-8 · Cited by 34
Chen, C. Y., & Tang, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80150 · Cited by 34
Ignoring the modeling approaches: Towards the shadowy paths in nanomedicine
Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.042 · Cited by 34
Wierling, C., Kühn, A., Hache, H., Daskalaki, A., Maschke-Dutz, E., Peycheva, S., Li, J., Herwig, R., & Lehrach, H. (2012) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2012.01.005 · Cited by 33
Employing dynamical computational models for personalizing cancer immunotherapy
Agur, Z., Halevi-Tobias, K., Kogan, Y., & Shlagman, O. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1223622 · Cited by 33
Using Metabolomics to Monitor Anticancer Drugs
Chung, Y., & Griffiths, J. R. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_089 · Cited by 32
Representing dynamic biological networks with multi-scale probabilistic models
Groß, A., Kracher, B., Kraus, J. M., Kühlwein, S. D., Pfister, A. S., Wiese, S., Luckert, K., Pötz, O., Joos, T., Van Daele, D., et al. (2019) · Communications Biology · doi:10.1038/s42003-018-0268-3 · Cited by 32
The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer
Bertoli, G. R., Cava, C., & Castiglioni, I. (2016) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2016.1208444 · Cited by 32
Fuzzy modeling of signal transduction networks
Huang, Z. J., & Hahn, J. (2009) · Chemical Engineering Science · doi:10.1016/j.ces.2009.01.041 · Cited by 31
Models of Models: A Translational Route for Cancer Treatment and Drug Development
Ogilvie, L. A., Kovachev, A., Wierling, C., Lange, B. M. H., & Lehrach, H. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00219 · Cited by 30
Network and systems biology: essential steps in virtualising drug discovery and development
Wierling, C., Keßler, T., Ogilvie, L. A., Lange, B. M. H., Yaspo, M., & Lehrach, H. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.07.002 · Cited by 28
Azad, A., Lawen, A., & Keith, J. M. (2015) · BMC Systems Biology · doi:10.1186/s12918-014-0135-x · Cited by 27
Freudenberg, R., Apolle, R., Walther, M., Hartmann, H., & Kotzerke, J. (2018) · EJNMMI Physics · doi:10.1186/s40658-018-0216-9 · Cited by 26
Article Commentary: Predictive Modeling of Drug Treatment in the Area of Personalized Medicine
Ogilvie, L. A., Wierling, C., Kessler, T., Lehrach, H., & Lange, B. M. H. (2015) · Cancer Informatics · doi:10.4137/cin.s19330 · Cited by 24
Elishmereni, M., Kheifetz, Y., Søndergaard, H., Overgaard, R. V., & Agur, Z. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002206 · Cited by 23
Bifurcation analysis for a mean field modelling of tumor and immune system competition
Angelis, E. D., Marasco, A., & Romano, A. (2003) · Mathematical and Computer Modelling · doi:10.1016/s0895-7177(03)00125-0 · Cited by 22
Delay differential equations and the dose-time dependence of early radiotherapy reactions
Fenwick, J. D. (2006) · Medical Physics · doi:10.1118/1.2241995 · Cited by 19
Structural Insights into the Osteopontin-Aptamer Complex by Molecular Dynamics Simulations
Penna, G. L., & Chelli, R. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00002 · Cited by 19
Computational modeling in melanoma for novel drug discovery
Pennisi, M., Russo, G., Di Salvatore, V., Candido, S., Libra, M., & Pappalardo, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1174688 · Cited by 18
Devlin, K. L., Sanford, T., Harrison, L. M., LeBourgeois, P., Lashinger, L. M., Mambo, E., & Hursting, S. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159686 · Cited by 18
Is standard multivariate analysis sufficient in clinical and epidemiological studies?
Cova, T. F. G. G., Pereira, J., & Pais, A. A. C. C. (2012) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2012.09.005 · Cited by 17
Self-citationGallaher, J. A., Babu, A., Plevritis, S. K., & Anderson, A. R. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0759 · Cited by 17
Immune system modelling by top-down and bottom-up approaches
Bianca, C., & Pennisi, M. A. (2012) · PORTO@Iris · Cited by 16
Improving Cancer Imaging With Magnetic Nanoparticles: Where are We now?
Tietze, R., & Alexiou, C. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0376 · Cited by 16
A review of computational approaches detecting microRNAs involved in cancer
Cantini, L., Caselle, M., Forget, A., Zinovyev, A., Barillot, E., & Martignetti, L. (2017) · Frontiers in bioscience · doi:10.2741/4571 · Cited by 15
Uncovering influence links in molecular knowledge networks to streamline personalized medicine
Shin, D., Arthur, G., Popescu, M., Korkin, D., & Shyu, C. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.08.003 · Cited by 14
RDF SKETCH MAPS - KNOWLEDGE COMPLEXITY REDUCTION FOR PRECISION MEDICINE ANALYTICS
Thanintorn, N., Wang, J., Ersoy, I., Al-Taie, Z., Jiang, Y., Wang, D., Verma, M., Joshi, T., Hammer, R., Xu, D. H., et al. (2015) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814749411_0038 · Cited by 14
Impact of the Arterial Input Function Recording Method on Kinetic Parameters in Small-Animal PET
Napieczyńska, H., Kolb, A., Katiyar, P., Tonietto, M., Ud‐Dean, M., Stumm, R., Herfert, K., Calaminus, C., & Pichler, B. J. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204164 · Cited by 14
Cava, C., Bertoli, G. R., Colaprico, A., Bontempi, G., Mauri, G., & Castiglioni, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030910 · Cited by 14
Logical versus kinetic modeling of biological networks: applications in cancer research
Calzone, L., Barillot, E., & Zinovyev, A. Y. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.02.005 · Cited by 14
The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment
Κάτσιλα, Θ., Liontos, M., Patrinos, G. P., Bamias, A., & Kardamakis, D. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.044 · Cited by 13
Kamps, K., Leek, R., Luebke, L., Price, R., Nelson, M., Simonet, S., Eggert, D. J., Ateşin, T. A., & Brown, E. M. B. (2012) · Integrative Biology · doi:10.1039/c2ib20166f · Cited by 12
Capozzi, E., Aureli, S., Minicozzi, V., Rossi, G. C., Stellato, F., & Morante, S. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.05.021 · Cited by 12
Reichel, D., Curtis, L. T., Ehlman, E., Evers, B. M., Rychahou, P. G., Frieboes, H. B., & Bae, Y. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2245-9 · Cited by 11
A pathologist-in-the-loop IHC antibody test selection using the entropy-based probabilistic method
Shin, D., Arthur, G., Caldwell, C. W., Popescu, M., Petruc, M., Diaz‐Arias, A. A., & Shyu, C. (2012) · Journal of Pathology Informatics · doi:10.4103/2153-3539.93393 · Cited by 10
Lopes, A. I. C., Cova, T. F. G. G., Pais, A. A. C. C., Pereira, J., Colaço, B., & Cabrita, A. (2013) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2013.09.001 · Cited by 8
Self-citationSensitivity evaluation and selective plane imaging geometry for x‐ray‐induced luminescence imaging
Quigley, B., Smith, C. D., Cheng, S., Souris, J. S., Pelizzari, C. A., Chen, C., Lo, L., Reft, C. S., Wiersma, R. D., & Rivière, P. J. L. (2017) · Medical Physics · doi:10.1002/mp.12470 · Cited by 8
A Spectral Fiedler Field-based Contrast Platform for Imaging of Nanoparticles in Colon Tumor
Liu, C.-N., Kapoor, A., VanOsdol, J., Ektate, K., Kong, Z., & Ranjan, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29675-1 · Cited by 7
Awojoyogbe, B. O., & Dada, M. O. (2018) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-018-0386-x · Cited by 6
Molecular level in silico studies for oncology. Direct models review
Psakhie, S. G., & Tsukanov, A. A. (2017) · AIP conference proceedings · doi:10.1063/1.5001637 · Cited by 2
From “One-Size-Fits-All” to a precision medicine approach in neurooncology and neurology practice
Kong, X. (2017) · Neurology and Clinical Neuroscience · Cited by 2
Solving cancer: The use of artificial neural networks in cancer diagnosis and treatment
Milani, C., & Jadavji, N. M. (2017) · Biochemistry and Molecular Biology Education · Cited by 2
Computational integrative analysis of biological networks in cancer
Liu, C. (2017) · Työväentutkimus Vuosikirja · Cited by 1
Kwok, Y., Kaiser, A., Rice, S. R., Cohen, R. J., & Mishra, M. V. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000440 · Cited by 1
Moving Away From a One-Size-Fits-All Approach to Gastric Cancer
Klute, K. A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00154 · Cited by 1
Research works printed but not linked: 3
- Morris, 2018, Big Data, Machine Learning, and Molecular Imaging, J. Nucl. Med., 59, 1159
- Chen, X., and Wong, S. (2014). Chapter 2—Genomics-Based Cancer Theranostics. Cancer Theranostics, Academic Press. · DOI
- Puri, M., Pathak, Y., Sutariya, V.K., Tipparaju, S., and Moreno, W. (2016). Chapter 14—ANN in Pharmaceutical Product and Process Development. Artificial Neural Network for Drug Design, Delivery and Disposition, Academic Press.
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Therefore, on the other side of the argument, interactions in reactive non-neoplastic cells, genetically-altered tumor cells, and ECM control the majority of the stages of tumorigenesis effectively including clonal evolution, cancer heterogeneity, epithelial-mesenchymaltransition (EMT), migration, invasion, developmen…”
BackgroundArtificial intelligence aids in development of nanomedicines for cancer management
Tan, P., Chen, X., Zhang, H., Wei, Q., & Luo, K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.005 · Cited by 246
Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review
Indoria, S., Singh, V., & Hsieh, M.-F. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119314 · Cited by 168
Novel therapeutic targets for cancer metastasis
Stoletov, K. V., Beatty, P. H., & Lewis, J. D. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1718496 · Cited by 109
Artificial intelligence and big data facilitated targeted drug discovery
Liu, B., He, H., Luo, H., Zhang, T., & Jiang, J. (2019) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000290 · Cited by 81
Metadata
- Authors
- Cova, T. F. G. G., Bento, D. J., & Nunes, S. C. C.
- Affiliations
- University of Coimbra (PT)
- Corresponding author
- Cova, Tânia F. G. G.
- Nunes, Sandra C. C.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-03-13
- Volume
- 11
- Issue
- 3
- Pages
- 119
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC6471740
- OpenAlex
- W2921183732
- Cited by
- 32
- References
- 178
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 2
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundação para a Ciência e a Tecnologia (016648 POCI − 01 − 0145 − FEDER − 016648; COMPETE POCI − 01 − 0145 − FEDER − 007440; PEst − OE/QUI/UI0313/2014; POCI − 01 − 0145 − FEDER − 007630; SFRH/BD/95459/2013; SFRH/BPD/71683/2010)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- cancer theranostics, computational modeling, data mining, predictive analytics, machine learning, artificial intelligence, cancer diagnosis, tumor heterogeneity, metastasis, drug resistance, molecular basis of cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.